Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.

PloS one - 1 Jan 2015

Dhayat Sameer A, Mardin Wolf Arif, Seggewiß Jochen, Ströse Anda Jana, Matuszcak Christiane, Hummel Richard, Senninger Norbert, Mees Sören Torge, Haier Jörg

Abstract excerpt

BACKGROUND: No reliable predictors of susceptibility to gemcitabine chemotherapy exist in pancreatic ductal adenocarcinoma (PDAC). MicroRNAs (miR) are epigenetic gene regulators with tumorsuppressive or oncogenic roles in various carcinomas. This study assesses chemoresistant PDAC for its specific miR expression pattern. METHODS: Gemcitabine-resistant variants of two mutant p53 human PDAC cell lines were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Drug Resistance, Neoplasm

Share to Gemcitabine

Share to Genes, p53

Share to Pancreatic Neoplasms

Share to RNA Interference

Source

Open in PubMed Open full text

Identifiers

PMID: 26606261
DOI: 10.1371/journal.pone.0143755
PMCID: PMC4659591

Genes

CDK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.PMID 26606261Read ↗

Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic CancerSemantic proximity Read ↗

Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overviewSemantic proximity Read ↗

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Semantic proximity Read ↗

MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potentialSemantic proximity Read ↗

Noncoding RNAs in drug-resistant pancreatic cancer: A reviewSemantic proximity Read ↗

Clinical Potential of MicroRNAs in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures.Semantic proximity Read ↗

Emerging role of microRNAs to tackle drug resistance in pancreatic cancerSemantic proximity Read ↗

Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer—A reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.